Skip to main content

Table 3 Adjusted mean difference (95% confidence interval) in change of secondary outcomes from baseline to 5-year follow-up between metformin initiators and non-initiators

From: Metformin use and respiratory outcomes in asthma-COPD overlap

Outcome

All participants (n = 2188)

Subgroup analysis

Asthma-COPD overlap (n = 278)

COPD (n = 1910)

p-interaction

St. George respiratory questionnaire total score

− 1 (− 4.1, 2.1)

− 10 (− 18.7, − 1.2)

0.27 (− 3, 3.6)

0.03

Six-Minute Walk Distance (ft)

5.2 (− 64, 74.4)

− 129.4 (− 337.7, 79)

23 (− 50.4, 96.5)

0.2

Post-Bronchodilator FEV1 percent predicted

1.4 (− 0.87, 3.7)

− 1.1 (− 7.7, 5.4)

1.8 (− 0.68, 4.3)

0.4

  1. Models are adjusted for age, sex, race, education, post-bronchodilator FEV1pp (time-varying, excluded for FEV1pp outcome), smoking status (time-varying), body mass index (time varying), inhaled corticosteroid use (time-varying), oral corticosteroid use (time-varying), other diabetes medication use, comorbidity count. The p-value shown is for the three-way interaction between metformin use, time, and Asthma-COPD overlap status. Lower St. George Respiratory Questionnaire score, higher six-minute walk distance, and higher FEV1 percent predicted favor metformin use. Bolded values are statistically significant at p < 0.05
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us